Psilocybin Depression Treatment Shows Shared Brain Mechanisms with Standard Antidepressants

Reported Candidozyma auris cases in Europe rose to 1,346 in 2023 across 18 countries, with several reporting regional or national spread. The fungus is highly transmissible, difficult to control, and often resistant to antifungal drugs, posing a significant challenge for hospitals. Europe’s limited surveillance and laboratory capacity leave the true scale of infections uncertain.

Too long to read? Go for the highlights below. Compass Pathways accelerates its planned commercial launch of COMP360 for treatment-resistant depression by up to a year after favourable engagement with the FDA. Phase 3 data remain the decisive hurdle, with key 9-week and 26-week readouts expected in early 2026. Despite rising losses linked to warrant liability adjustments, the company reports a strengthened cash position sufficient to operate into 2027. Regulatory momentum and

Too long to read? Go for the highlights below. Finnish biotechnology firm Kääpä Biotech  has closed a €9 million strategic investment led by PeakBridge and Zintinus to expand production capacity and strengthen its position in the global nutraceutical market The funding will enable vertical integration expansion and scale operations to meet surging international demand from over 180 companies across 20+ markets This marks PeakBridge's second investment in Kääpä following a €90

This is the second article in a six-part series exploring critical themes shaping the future of functional mushrooms, in partnership with Finnish biotech company KÄÄPÄ Biotech . In the evolving landscape of the functional mushroom industry, transparency has emerged as a cornerstone of consumer trust, product integrity, and scientific credibility. As the functional mushroom market rapidly grows ( see the first article in this series by KÄÄPÄ Biotech ), together with the trendi